RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
Aim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease aged under 70 years were involved into the crossover study. Clinical examination included questionnair...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/544 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227857706876928 |
|---|---|
| author | A. A. Lomonosova N. A. Mazur E. A. Zolozova E. V. Sayutina V. V. Chigineva N. V. Shestakova |
| author_facet | A. A. Lomonosova N. A. Mazur E. A. Zolozova E. V. Sayutina V. V. Chigineva N. V. Shestakova |
| author_sort | A. A. Lomonosova |
| collection | DOAJ |
| description | Aim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease aged under 70 years were involved into the crossover study. Clinical examination included questionnaire survey , blood pressure (BP) measurement, ECG registration, 24-hour ECG and BP monitoring, determination of blood levels of total cholesterol, high density lipoproteins, triglycerides, transaminases, and creatinine, complete blood cell count, including platelets number and hemoglobin level. Besides evaluation of the platelet aggregation by optical aggregometry was performed initially , after one week ASA treatment and after every next 3 week clopidogrel treatment period. Results. RPAR during ASA monotherapy was 56.4±0.3%. There were no significant differences in effects of original and generic clopidogrel on RPAR. Сlopidogrel therapy reduced RPAR more significantly (42.2±0.2%) than ASA monotherapy did (p=0.0003). Authors proposed definition for high level of RPAR during therapy - it is platelet aggregation more than 46%. Data analysis taking into account this criterion showed that a number of patients with high RPAR was 70 and 30% among patients treated with enterosoluble ASA and clopidogrel, respectively. Conclusion. Study results show that a significant number of patients receiving antiplatelet monotherapy does not achieve the target level of RPAR(<46%). These results may be a rationale for combined therapy in patients of this type. |
| format | Article |
| id | doaj-art-432ab3f601df4b6dae68f5ff8ff532bc |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-12-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-432ab3f601df4b6dae68f5ff8ff532bc2025-08-23T10:00:20ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-018216817210.20996/1819-6446-2012-8-2-12-25544RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORSA. A. Lomonosova0N. A. Mazur1E. A. Zolozova2E. V. Sayutina3V. V. Chigineva4N. V. Shestakova5Russian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate EducationAim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease aged under 70 years were involved into the crossover study. Clinical examination included questionnaire survey , blood pressure (BP) measurement, ECG registration, 24-hour ECG and BP monitoring, determination of blood levels of total cholesterol, high density lipoproteins, triglycerides, transaminases, and creatinine, complete blood cell count, including platelets number and hemoglobin level. Besides evaluation of the platelet aggregation by optical aggregometry was performed initially , after one week ASA treatment and after every next 3 week clopidogrel treatment period. Results. RPAR during ASA monotherapy was 56.4±0.3%. There were no significant differences in effects of original and generic clopidogrel on RPAR. Сlopidogrel therapy reduced RPAR more significantly (42.2±0.2%) than ASA monotherapy did (p=0.0003). Authors proposed definition for high level of RPAR during therapy - it is platelet aggregation more than 46%. Data analysis taking into account this criterion showed that a number of patients with high RPAR was 70 and 30% among patients treated with enterosoluble ASA and clopidogrel, respectively. Conclusion. Study results show that a significant number of patients receiving antiplatelet monotherapy does not achieve the target level of RPAR(<46%). These results may be a rationale for combined therapy in patients of this type.https://www.rpcardio.online/jour/article/view/544platelet aggregationresidual reactivityischemic heart diseaseacetylsalicylic acidclopidogrel |
| spellingShingle | A. A. Lomonosova N. A. Mazur E. A. Zolozova E. V. Sayutina V. V. Chigineva N. V. Shestakova RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS Рациональная фармакотерапия в кардиологии platelet aggregation residual reactivity ischemic heart disease acetylsalicylic acid clopidogrel |
| title | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS |
| title_full | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS |
| title_fullStr | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS |
| title_full_unstemmed | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS |
| title_short | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS |
| title_sort | residual platelet reactivity during therapy with inhibitors of cyclooxigenase or adenosine diphosphate receptors |
| topic | platelet aggregation residual reactivity ischemic heart disease acetylsalicylic acid clopidogrel |
| url | https://www.rpcardio.online/jour/article/view/544 |
| work_keys_str_mv | AT aalomonosova residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors AT namazur residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors AT eazolozova residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors AT evsayutina residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors AT vvchigineva residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors AT nvshestakova residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors |